NCT04761185View on ClinicalTrials.gov

Raltitrexed in HIPEC

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

November 30, 2024

Study Completion Date

April 30, 2025

Conditions
Colorectal CancerRaltitrexedHIPEC
Interventions
DRUG

Raltitrexed

The RTX-HIPEC protocol used a modified Fibonacci dose escalation method with 7 dose levels (3, 4, 5, 6, 7, 8, 9 mg/m2)

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT04761185 - Raltitrexed in HIPEC | Biotech Hunter | Biotech Hunter